Baird Downgrades Cogent (COGT) to Neutral, 'fairly valued around these levels'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Cogent (COGT) PT Raised to $13 at Citi
February 26, 2024 2:58 AM ESTCiti analyst David Lebowitz raised the price target on Cogent (NASDAQ: COGT) to $13.00 (from $11.00) while maintaining a Buy rating.... More
Cogent (COGT) PT Raised to $18 at Needham & Company
February 23, 2024 7:33 AM ESTNeedham & Company analyst Ami Fadia raised the price target on Cogent (NASDAQ: COGT) to $18.00 (from $15.00) while maintaining a Buy rating.... More
Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
February 22, 2024 2:30 PM ESTCogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive Part 1b data from the Companys ongoing SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM) at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) meeting taking place February 23-26, 2024 in Washington, D.C.
The... More
